Replies to post #22597 on Regen BioPharma Inc (RGBP)

[SidVicious]

Mando, The funds for NCATS FY 2016 are set and they are dedicated to that branchof the NIH. What ever money the gov lab uses to screen is for that lab and for that lab only. None of the budgeted money is for Regen to use. NCATS is not cutting a check to REGEN. I don't know how it could be any more clearer than that. All REGEN is utilizing is the NCATS lab that is funded. IOW, REGEN has the full resources of the lab that they will have use for at the tax payer's expense. Regen pays nothing for its use other than supplying the cell lines but the NCATS isn't paying anything to REGEN. If I am wrong, please correct me as to what NCATS is paying REGEN?

MY whole point all along is no money is being given to REGEN. If you want to argue that NCATS resources are and that is a form of payment then ok, I agree but no grant money, check, cash, or any form of currency is being given to REGEN.

Again, I have no idea why this is so hard for some to understand.

[1~Eye~Jack!!]

~ RGBP = IT IS VERY CLEAR =.The~JV~thru~NIH~is~COMPLETELY~FUNDED!! ;-)

That is Why the 8k is such HUGE New$!! ;-)

RGBP,, NCATS, NIH, arRre NOT Allowed to disclose the Information of How much Money this is,, or how much Costs arRre!!
IMO,, its final Costs arRre not completely known,, but make NO Mistake,, this Collaboration is COMPLETELY FUNDED!! ...and for up to 3 Years!! ;-)

I Suggest EVERYONE Read the whole 8k! ;-)
...but here is the Funding Part! ;-)...it was so Important it was #1 on da Agreement, YO! ;-)
http://ih.advfn.com/p.php?pid=nmona&article=69735998

Background
1. NCATS and Collaborator want to collaborate on a research project; and
2. NCATS and Collaborator want to transfer between the laboratories of their investigators, during the term of this Agreement, confidential information and proprietary research materials required to conduct the research project.

Terms and Conditions

Article 1 DEFINITIONS
1.1 “Confidential Information” includes scientific, business, or financial information pertaining to the Research Project (defined below) that is designated as confidential by Provider (defined below). Confidential Information does not include information that: (i) is in the public domain other than as a result of a disclosure by Recipient (defined below) or any of Recipient’s representatives in violation of this Agreement; (ii) was in the possession of Recipient before disclosure by the Provider; (iii) is acquired by Recipient from a third party having no obligation of confidentiality to Provider; (iv) is hereafter independently developed by Recipient, without reference to Confidential Information received from Provider; or (v) Provider expressly authorizes Recipient to disclose.

...and there is Money to be Gained from the HUGE JV!!! ;-)

http://ih.advfn.com/p.php?pid=nmona&article=69735998

On December 15, 2015 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with the National Center for Advancing Translational Sciences (“NCATS”), which is a component of the National Institutes of Health (“NIH”), an agency of the U.S. Department of Health and Human Services

Inventions made in the course of the Research Project will be owned by the Party employing the inventor or inventors. Inventions that are invented jointly by employees of both Parties will be owned jointly.

The Parties, moreover, agree to enter into an inter-institutional agreement with respect to joint inventions, which shall authorize Regen to have primary control and responsibility for any patenting and commercialization activities and shall be negotiated in good faith based on the respective parties’ contributions to each Joint Invention.

This is Why I'm on a Boat Crui$e'n~NorRrth, YO!! ;-) ...& with my Flippy~Floppy$,,YO!! ;-)